Athero-Blocker – New peptides for the prevention and treatment of atherosclerosis
Scientists at the RWTH Aachen have identified new
peptides which can be used for the prevention of atherosclerosis or in the treatment of related cardiovascular diseases. It is known that adherent activated platelets secrete chemoattractants, such as the chemokines PF4 and RANTES, which are responsible for monocyterecruitment. Receptor-blocking experiments and studies with knock-out mice indicated that RANTES signals contribute to intimal hyperplasia and macrophage infiltration in models of restenosis. Moreover, it plays an important role in the initiation and maintenance of atherosclerosis. Athero-Blocker is specifically targeting the interaction between the chemokines RANTES and PF4. It can thereby abrogate the proatherogenic enhancement of monocyte recruitment caused by this interaction. A good efficacy of Athero-Blocker has been demonstrated in in vitro experiments, in cell based test systems and in mouse models in vivo.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…
